TRENDS

Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers

April 3, 2018
By Reiji Anasako Eisai is offloading its generic subsidiary Elmed Eisai to Japan’s largest generic maker, Nichi-Iko Pharmaceutical. Among innovative pharma companies, it is the first divestment of a generic business since one by Mitsubishi Tanabe Pharma a year ago,…

To read the full story

Related Article

TRENDS

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…